Oxycodone side effects: what 185,825 FDA adverse event reports show
Drug class
Not stated in label
Brand names
Oxycodone Hydrochloride
Who reports
185,825 reports · 82% serious · 53,015 with death outcome · 54% female
Used for
Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.
What it is
Oxycodone is a semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.
Boxed warning
SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,146 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| C-reactive protein | 527 | 157.6 138.0–180.0ROR 158.0 · calibrated p 3e-9 ✓ | 65.3 EB05 60.8 · IC025 +5.8 3/3 methods agree | Lab value / disease marker | serious n=527 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Facet joint syndrome | 1,653 | 125.0 116.5–134.1ROR 126.1 · calibrated p 2e-8 ✓ | 59.1 EB05 56.7 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=1,653 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Deep vein thrombosis postoperative | 981 | 113.3 103.7–123.9ROR 113.9 · calibrated p 4e-8 ✓ | 56.4 EB05 53.5 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious n=981 · ♀ 100% (drug 54%) · 91% clinician | no trial arm names this drug |
| Duodenal ulcer perforation | 3,547 | 105.8 101.1–110.8ROR 107.8 · calibrated p 6e-8 ✓ | 54.5 EB05 53.0 · IC025 +5.7 3/3 methods agree | Not in label — unassessed | serious PRR 38.4 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Rheumatic fever | 1,971 | 92.9 87.5–98.6ROR 93.9 · calibrated p 2e-7 ✓ | 50.9 EB05 49.0 · IC025 +5.6 3/3 methods agree | Not in label — unassessed | serious n=1,971 · ♀ 100% (drug 54%) · 96% clinician | no trial arm names this drug |
| Muscle injury | 3,699 | 92.7 88.8–96.8ROR 94.6 · calibrated p 2e-7 ✓ | 50.8 EB05 49.5 · IC025 +5.6 3/3 methods agree | Labeled (related wording) related wording | serious PRR 38.8 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| Swollen joint count increased | 1,363 | 87.6 81.6–94.1ROR 88.3 · calibrated p 3e-7 ✓ | 49.3 EB05 47.1 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious n=1,363 · ♀ 100% (drug 54%) · 97% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody positive | 3,058 | 85.3 81.4–89.4ROR 86.7 · calibrated p 3e-7 ✓ | 48.5 EB05 47.1 · IC025 +5.5 3/3 methods agree | Lab value / disease marker | serious PRR 34.3 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| Lupus vulgaris | 488 | 78.4 69.8–88.0ROR 78.6 · calibrated p 7e-7 ✓ | 46.2 EB05 42.8 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=488 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Sleep disorder due to general medical condition, insomnia type | 2,636 | 78.2 74.4–82.2ROR 79.3 · calibrated p 6e-7 ✓ | 46.2 EB05 44.7 · IC025 +5.5 3/3 methods agree | Labeled (related wording) related wording | serious n=2,630 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| Folliculitis | 4,193 | 77.1 74.1–80.2ROR 78.8 · calibrated p 6e-7 ✓ | 45.8 EB05 44.6 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious PRR 37.9 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Red blood cell sedimentation rate | 114 | 76.7 60.4–97.4ROR 76.7 · calibrated p 1e-6 ✓ | 45.3 EB05 38.8 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=114 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Subcutaneous drug absorption impaired | 220 | 76.3 64.3–90.6ROR 76.4 · calibrated p 9e-7 ✓ | 45.4 EB05 40.5 · IC025 +5.1 3/3 methods agree | Labeled (related wording) related wording | serious n=219 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Anti-cyclic citrullinated peptide antibody | 269 | 76.1 65.2–88.9ROR 76.2 · calibrated p 9e-7 ✓ | 45.3 EB05 40.9 · IC025 +5.2 3/3 methods agree | Lab value / disease marker | serious n=269 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Adjustment disorder with depressed mood | 747 | 66.3 60.6–72.6ROR 66.6 · calibrated p 2e-6 ✓ | 41.8 EB05 39.3 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=744 · ♀ 100% (drug 54%) · 96% clinician | no trial arm names this drug |
| Swollen joint count | 91 | 66.1 50.9–85.6ROR 66.1 · calibrated p 3e-6 ✓ | 41.4 EB05 34.7 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=91 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Hypocholesterolaemia | 112 | 64.4 51.0–81.2ROR 64.4 · calibrated p 3e-6 ✓ | 40.8 EB05 34.8 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=112 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Drug diversion | 2,013 | 61.1 57.8–64.5ROR 61.7 · calibrated p 3e-6 ✓ | 39.6 EB05 38.2 · IC025 +5.2 3/3 methods agree | Reporting / coding artifact | serious n=1,047 · 95% consumer | no trial arm names this drug |
| Helicobacter infection | 3,544 | 60.0 57.6–62.5ROR 61.1 · calibrated p 4e-6 ✓ | 39.2 EB05 38.1 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious PRR 29.2 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Dislocation of vertebra | 725 | 54.4 49.8–59.4ROR 54.6 · calibrated p 8e-6 ✓ | 36.7 EB05 34.5 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=725 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Peripheral venous disease | 1,261 | 51.9 48.5–55.5ROR 52.2 · calibrated p 1e-5 ✓ | 35.6 EB05 34.0 · IC025 +5.0 3/3 methods agree | Labeled (related wording) related wording | serious n=1,258 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| X-ray abnormal | 546 | 49.5 44.8–54.8ROR 49.7 · calibrated p 1e-5 ✓ | 34.5 EB05 32.1 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=545 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Pemphigus | 3,679 | 47.2 45.5–49.1ROR 48.2 · calibrated p 2e-5 ✓ | 33.4 EB05 32.5 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious PRR 23.6 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| C-reactive protein abnormal | 1,801 | 43.9 41.6–46.4ROR 44.4 · calibrated p 3e-5 ✓ | 31.7 EB05 30.5 · IC025 +4.9 3/3 methods agree | Lab value / disease marker | serious n=1,801 · ♀ 85% (drug 54%) · 92% clinician | no trial arm names this drug |
| Rheumatoid factor positive | 1,576 | 42.2 39.8–44.7ROR 42.6 · calibrated p 4e-5 ✓ | 30.8 EB05 29.5 · IC025 +4.8 3/3 methods agree | Lab value / disease marker | serious n=1,576 · ♀ 100% (drug 54%) · 97% clinician | no trial arm names this drug |
| Hand deformity | 3,512 | 41.2 39.7–42.8ROR 42.0 · calibrated p 4e-5 ✓ | 30.3 EB05 29.4 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious PRR 23.2 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| Retinitis | 434 | 39.4 35.4–44.0ROR 39.5 · calibrated p 6e-5 ✓ | 29.3 EB05 27.0 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=434 · ♀ 100% (drug 54%) · 100% clinician | no trial arm names this drug |
| Pericarditis | 3,600 | 30.9 29.8–32.1ROR 31.5 · calibrated p 2e-4 ✓ | 24.4 EB05 23.7 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious PRR 17.3 · ♀ 100% (drug 54%) · 93% clinician | no trial arm names this drug |
| Victim of homicide | 121 | 30.5 25.0–37.4ROR 30.6 · calibrated p 3e-4 ✓ | 24.1 EB05 20.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=121 · ♀ 0% (drug 54%) · 100% consumer | no trial arm names this drug |
| Synovitis | 3,825 | 30.2 29.1–31.3ROR 30.8 · calibrated p 2e-4 ✓ | 23.9 EB05 23.3 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious PRR 17.6 · ♀ 97% (drug 54%) · 93% clinician | no trial arm names this drug |
| Irritable bowel syndrome | 4,168 | 27.2 26.3–28.1ROR 27.8 · calibrated p 4e-4 ✓ | 22.0 EB05 21.4 · IC025 +4.4 3/3 methods agree | Not in label — unassessed | serious PRR 19.6 · ♀ 99% (drug 54%) · 92% clinician | no trial arm names this drug |
| Breast cancer stage iii | 1,241 | 26.8 25.2–28.5ROR 27.0 · calibrated p 5e-4 ✓ | 21.7 EB05 20.8 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=1,241 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Lip dry | 1,700 | 26.3 24.9–27.7ROR 26.5 · calibrated p 5e-4 ✓ | 21.4 EB05 20.6 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=1,681 · ♀ 100% (drug 54%) · 94% clinician | no trial arm names this drug |
| Toxic leukoencephalopathy | 125 | 23.3 19.2–28.3ROR 23.4 · calibrated p 0.001 ✓ | 19.4 EB05 16.7 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=125 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Steroid dependence | 145 | 23.1 19.3–27.6ROR 23.1 · calibrated p 0.001 ✓ | 19.2 EB05 16.7 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=145 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Drug dependence | 27,708 | 23.0 22.7–23.3ROR 26.9 · calibrated p 5e-4 ✓ | 19.2 EB05 19.0 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 8.5 · serious PRR 13.8 · 90% consumer | no trial arm names this drug |
| Glossodynia (burning tongue/mouth pain) | 3,759 | 22.7 21.9–23.5ROR 23.1 · calibrated p 1e-3 ✓ | 19.0 EB05 18.5 · IC025 +4.2 3/3 methods agree | Labeled (related wording) related wording | serious PRR 19.0 · ♀ 98% (drug 54%) · 91% clinician | no trial arm names this drug |
| Catarrh | 148 | 22.4 18.7–26.7ROR 22.4 · calibrated p 0.001 ✓ | 18.7 EB05 16.3 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=148 · ♀ 0% (drug 54%) · 100% clinician | no trial arm names this drug |
| Onychomadesis | 682 | 22.0 20.3–23.9ROR 22.1 · calibrated p 0.001 ✓ | 18.5 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=676 · ♀ 100% (drug 54%) · 91% clinician | no trial arm names this drug |
| Opisthotonus | 130 | 21.7 18.0–26.2ROR 21.7 · calibrated p 0.001 ✓ | 18.3 EB05 15.8 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=130 | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Dependence / withdrawal | 30,927 | 13.112.9–13.2 | signal |
| Liver injury | 7,006 | 2.72.6–2.7 | signal |
| Suicidality | 5,321 | 2.52.4–2.5 | signal |
| Interstitial lung disease | 1,857 | 2.22.1–2.3 | signal |
| Depression | 5,400 | 2.22.1–2.2 | signal |
| Serious infection | 13,076 | 1.91.9–2.0 | raised |
| Venous thromboembolism | 2,874 | 1.51.5–1.6 | raised |
| Kidney injury | 5,910 | 1.51.4–1.5 | raised |
| Fall / fracture | 4,902 | 1.51.4–1.5 | raised |
| Hyperglycaemia / diabetes | 4,030 | 1.31.3–1.4 | raised |
| Thrombocytopenia | 2,553 | 1.31.3–1.4 | raised |
| Hyponatraemia | 930 | 1.31.2–1.4 | raised |
| Tendon disorder | 435 | 1.31.2–1.4 | raised |
| Rhabdomyolysis / myopathy | 886 | 1.21.2–1.3 | raised |
| Anaemia | 3,220 | 1.21.2–1.3 | raised |
| Gi bleeding | 1,876 | 1.21.1–1.2 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug dependence | 27,708 | 23.0 22.7–23.3ROR 26.9 · calibrated p 5e-4 ✓ | 19.2 EB05 19.0 · IC025 +4.2 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 8.5 · serious PRR 13.8 · 90% consumer | no trial arm names this drug |
| Pain | 26,899 | 5.1 5.1–5.2ROR 5.8 · calibrated p 0.163 | 4.9 EB05 4.9 · IC025 +2.3 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 2.9 · serious PRR 5.0 | no trial arm names this drug |
| Death | 19,843 | 2.6 2.6–2.7ROR 2.8 · calibrated p 0.683 | 2.6 EB05 2.6 · IC025 +1.4 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | age-adj. PRR 1.7 · serious PRR 1.8 | no trial arm names this drug |
| Overdose | 19,262 | 10.9 10.8–11.1ROR 12.1 · calibrated p 0.016 ✓ | 10.0 EB05 9.9 · IC025 +3.3 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 3.5 · serious PRR 8.9 · 70% consumer | no trial arm names this drug |
| Toxicity to various agents | 16,484 | 12.2 12.0–12.4ROR 13.3 · calibrated p 0.011 ✓ | 11.1 EB05 10.9 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 5.7 · serious PRR 8.0 | no trial arm names this drug |
| Emotional distress | 15,683 | 16.6 16.3–16.9ROR 18.0 · calibrated p 0.003 ✓ | 14.6 EB05 14.4 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.3 · serious PRR 11.1 · 89% consumer | no trial arm names this drug |
| Fatigue (tiredness) | 12,384 | 1.8 1.8–1.8ROR 1.9 · calibrated p 0.871 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 1.8 | no trial arm names this drug |
| Drug ineffective (drug did not work) | 11,892 | 1.0 1.0–1.0ROR 1.0 · calibrated p 0.320 | 1.0 EB05 1.0 · IC025 -0.0 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 1.4 | no trial arm names this drug |
| Nausea | 11,147 | 1.6 1.6–1.6ROR 1.6 · calibrated p 0.732 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 1.5 | no trial arm names this drug |
| Drug withdrawal syndrome | 10,522 | 15.1 14.8–15.4ROR 15.9 · calibrated p 0.005 ✓ | 13.4 EB05 13.2 · IC025 +3.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 4.1 · serious PRR 11.5 | no trial arm names this drug |
| Off label use (used outside approved label) | 8,757 | 1.1 1.1–1.2ROR 1.1 · calibrated p 0.404 | 1.1 EB05 1.1 · IC025 +0.2 | Reporting / coding artifact | age-adj. PRR 1.5 · serious PRR 1.2 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 8,619 | 1.5 1.5–1.6ROR 1.5 · calibrated p 0.670 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 1.4 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 8,078 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.737 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 1.4 · ♀ 74% (drug 54%) | no trial arm names this drug |
| Vomiting | 7,912 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.922 | 1.9 EB05 1.9 · IC025 +0.9 | Labeled adverse reaction exact term | age-adj. PRR 2.2 · serious PRR 1.7 · ♀ 74% (drug 54%) | no trial arm names this drug |
| Rash | 7,686 | 2.0 2.0–2.1ROR 2.1 · calibrated p 0.978 | 2.0 EB05 2.0 · IC025 +1.0 | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.7 · ♀ 82% (drug 54%) | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Facet joint syndrome — n=1,653, PRR 125.0
- Deep vein thrombosis postoperative — n=981, PRR 113.3
- Duodenal ulcer perforation — n=3,547, PRR 105.8
- Rheumatic fever — n=1,971, PRR 92.9
- Lupus vulgaris — n=488, PRR 78.4
- Folliculitis — n=4,193, PRR 77.1
- Adjustment disorder with depressed mood — n=747, PRR 66.3
- Swollen joint count — n=91, PRR 66.1
- Hypocholesterolaemia — n=112, PRR 64.4
- Helicobacter infection — n=3,544, PRR 60.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Oxycodone?
In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone are pain, toxicity to various agents, emotional distress, fatigue, nausea, drug withdrawal syndrome. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Oxycodone have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.
Do FAERS signals prove that Oxycodone causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 6b6db42b-9821-4aa6-8566-297037d84079, effective 20260723; matched on
openfda.generic_name.exact:"OXYCODONE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 5284603 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,186 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
OXYCODONE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.